223 related articles for article (PubMed ID: 19175378)
1. Reverse cholesterol transport in type 2 diabetes mellitus.
Tan KC
Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378
[TBL] [Abstract][Full Text] [Related]
2. New insights into the regulation of HDL metabolism and reverse cholesterol transport.
Lewis GF; Rader DJ
Circ Res; 2005 Jun; 96(12):1221-32. PubMed ID: 15976321
[TBL] [Abstract][Full Text] [Related]
3. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
Hersberger M; von Eckardstein A
Handb Exp Pharmacol; 2005; (170):537-61. PubMed ID: 16596814
[TBL] [Abstract][Full Text] [Related]
4. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.
El Khoury P; Waldmann E; Huby T; Gall J; Couvert P; Lacorte JM; Chapman J; Frisdal E; Lesnik P; Parhofer KG; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):285-94. PubMed ID: 26681758
[TBL] [Abstract][Full Text] [Related]
5. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
[TBL] [Abstract][Full Text] [Related]
6. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Briand F; Thieblemont Q; Muzotte E; Sulpice T
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
[TBL] [Abstract][Full Text] [Related]
7. HDL elevation and lipid lowering therapy: current scenario and future perspectives.
Chhabria MT; Suhagia BN; Brahmkshatriya PS
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):214-27. PubMed ID: 18221121
[TBL] [Abstract][Full Text] [Related]
8. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
Catalano G; Julia Z; Frisdal E; Vedie B; Fournier N; Le Goff W; Chapman MJ; Guerin M
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):268-75. PubMed ID: 19038848
[TBL] [Abstract][Full Text] [Related]
9. Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins.
Gillard BK; Rosales C; Xu B; Gotto AM; Pownall HJ
J Clin Lipidol; 2018; 12(4):849-856. PubMed ID: 29731282
[TBL] [Abstract][Full Text] [Related]
10. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
Bellanger N; Julia Z; Villard EF; El Khoury P; Duchene E; Chapman MJ; Fournier N; Le Goff W; Guerin M
Atherosclerosis; 2012 Mar; 221(1):160-8. PubMed ID: 22265126
[TBL] [Abstract][Full Text] [Related]
11. Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes.
Wu ZH; Zhao SP
Pharmacology; 2009; 84(5):282-7. PubMed ID: 19797938
[TBL] [Abstract][Full Text] [Related]
12. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis.
Krause BR; Auerbach BJ
Curr Opin Investig Drugs; 2001 Mar; 2(3):375-81. PubMed ID: 11575708
[TBL] [Abstract][Full Text] [Related]
13. What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?
Sorci-Thomas MG; Pollard RD; Thomas MJ
Curr Opin Lipidol; 2015 Oct; 26(5):420-5. PubMed ID: 26218419
[TBL] [Abstract][Full Text] [Related]
14. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia.
Bellanger N; Orsoni A; Julia Z; Fournier N; Frisdal E; Duchene E; Bruckert E; Carrie A; Bonnefont-Rousselot D; Pirault J; Saint-Charles F; Chapman MJ; Lesnik P; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1675-81. PubMed ID: 21527752
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic strategies to enhance HDL function.
Redondo S; Martínez-González J; Urraca C; Tejerina T
Lipids Health Dis; 2011 Oct; 10():175. PubMed ID: 21985435
[TBL] [Abstract][Full Text] [Related]
16. Nuclear receptors as potential targets for modulating reverse cholesterol transport.
Pelton PD; Patel M; Demarest KT
Curr Top Med Chem; 2005; 5(3):265-82. PubMed ID: 15857310
[TBL] [Abstract][Full Text] [Related]
17. [New trends in lipidology: the increasing role of HDL-cholesterol].
Paragh G; Harangi M; László M
Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor.
Zhou H; Li Z; Silver DL; Jiang XC
Biochim Biophys Acta; 2006 Dec; 1761(12):1482-8. PubMed ID: 17055779
[TBL] [Abstract][Full Text] [Related]
19. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice.
Nijstad N; Gautier T; Briand F; Rader DJ; Tietge UJ
Gastroenterology; 2011 Mar; 140(3):1043-51. PubMed ID: 21134376
[TBL] [Abstract][Full Text] [Related]
20. Reverse cholesterol transport and cholesterol efflux in atherosclerosis.
Ohashi R; Mu H; Wang X; Yao Q; Chen C
QJM; 2005 Dec; 98(12):845-56. PubMed ID: 16258026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
